Mary Armanios, M.D.,– associate professor of oncology
Dr. Armanios’ clinical and research interests focus on disorders caused by telomere dysfunction. Her goal is to define approaches to surveillance, diagnosis and treatment for patients with telomere-mediated disease including dyskeratosis congenia. She directs the Telomere Clinic in the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which provides multidisciplinary care to patients who are suspected to have or who carry the diagnosis of telomere-related disorders, including cancer, bone marrow failure/aplastic anemia, lung disease and liver cirrhosis. Her team also has ongoing research efforts including a long-term study to understand the genetics and spectrum of telomere disorders through a registry housed at Johns Hopkins since 2005.
Robert Brodsky, M.D., – director, Division of Hematology, and professor of medicine and oncology
Dr. Brodsky’s clinical research involves the study of aplastic anemia, paroxysmal nocturnal hemoglobinuria (PNH), and other bone marrow failure disorders. His work has demonstrated that high doses of the drug cyclophosphamide, without bone marrow transplantation, can lead to durable complete remissions in severe aplastic anemia. He and his colleagues in neurology and rheumatology are applying this approach in other severe autoimmune disorders such as scleroderma, myasthenia gravis, multiple sclerosis and autoimmune hematologic disorders. Dr. Brodsky’s major laboratory interests relate to the study of normal and abnormal blood cell development, including studies of PIG-A gene mutations in aplastic anemia. His group has developed a novel diagnostic assay for PNH based on the pore-forming toxin aeromonas hydrophila.
Hetty Carraway, M.D., MBA – assistant professor of oncology
Dr. Carraway is a translational clinical scientist, with a research focus on experimental therapeutics of acute leukemias, including using novel biological agents (such as epigenetic agents) for adults with acute leukemias as well as new approaches to the treatment of refractory acute leukemias. She is an active participant in national clinical research group studies for adult lymphocytic leukemia.
Amy DeZern, M.D., -- assistant professor of medicine and oncology
Dr. DeZern is a clinical investigator with a focused interest in diagnosing and treating undifferentiated bone marrow failure disorders. In addition to maintaining an active research program, she sees patients with acute leukemia and all types of bone marrow failure. She has particular experience and expertise in the diagnosis and management of aplastic anemia, myelodysplastic syndrome and acute leukemia, and immune-mediated cytopenias.
Steven Gore, M.D., – professor of oncology
Dr. Gore’s clinical interests include epigenetics, myelodysplasia, and acute and chronic adult leukemias. His research studies the development of novel effective therapies for the treatment of abnormal bone marrow cells, including myelodysplastic syndromes, and he is currently focused on the development of drugs that inhibit histone deacetylase activity.
Richard Jones, M.D., – director, Bone Marrow Transplant Program; co-director, Hematologic Malignancies Program; professor of oncology and medicine
Research is to better understand the biology of normal and abnormal blood cell development, with an eye to improving the treatment of blood disorders by translating promising findings to the clinic. A primary area of focus is the identification and biologic characterization of cancer stem cells.
Michael McDevitt, M.D., – assistant professor of medicine and oncology
Dr. McDevitt specializes in the class evaluation of anemias, thrombocytopenias, and other hematology disorders. His research interests include the identification and characterization of tumor suppressor genes on chromosome 7 that contribute to the development of bone marrow cancers.
B. Douglas Smith, M.D., – associate professor of oncology
Dr. Smith’s research focuses on taking new, promising laboratory insights and developing them into biology-based treatment approaches for patients with acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and myelodysplastic syndrome (MDS).
Collaborators in the Division of Hematology, Johns Hopkins School of Medicine:
Allison Moliterno, M.D., – associate professor of medicine
Dr. Moliterno’s clinical research involves the study of chronic myeloproliferative disorders including polycythemia vera, essential thrombocytosis and idiopathic myelofibrosis. Her research focuses on genetic and epigenetic lesions associated with MPDs with the goal of improving diagnosis and treatment for these disorders.
Jerry Spivak, M.D., – director, Center for the Chronic Myeloproliferative Disorders, and professor of medicine and oncology
Dr. Spivak’s research interests focused on chronic myeloproliferative disorders with particular emphasis on the molecular basis of these disorders and the means for distinguishing them both diagnostically and with respect to therapeutic intervention. Using techniques to analyze gene expression in polycythemia vera stem cells, he has found that polycythemia vera patients can be distinguished from patients with erythrocytosis and also divided into two groups: those with aggressive disease versus less aggressive. He and his colleagues also are studying the role of specific molecular markers identified at Johns Hopkins and elsewhere related to the development and diagnosis of polycythemia vera.
Collaborator in Pediatrics, Johns Hopkins School of Medicine:
Heather Symons, M.D., MHS, – assistant professor of oncology
Dr. Symons, a pediatric oncologist, has several research interests in addition to caring for patients. One project focuses on using a novel immunotherapy approach to treating both solid tumors and hematologic (blood-borne) malignancies. Evaluating an experimental therapy, Dr. Symons is pairing donor lymphocytes (white blood cells that activate the body's immune system) with chemotherapy to determine if this combination will jumpstart patients’ immune systems attack cancer cells. In another project, she is examining ways to reduce bone marrow transplant-related complications ordinarily associated with some donors after high-dose chemotherapy.